Ascent Biomedical Ventures (ABV) is a venture capital firm investing in seed and early-stage biomedical technology companies developing medical devices, biopharmaceuticals, healthcare services, and information technology. ABV's principals and advisors work closely with entrepreneurs to manage the risks associated with deploying capital in startup companies.

ABV's investment strategy relies on:

(i) Seed- and early-stage focus.
ABV will invest in seed- and early-stage companies in the biomedical technology segment of the healthcare industry, where the rapidly increasing rate of ideation has lead to unprecedented opportunities to successfully commercialize innovation;

(ii) Engaged clinical and scientific network.
The commercial success of novel technologies is often driven by the support of key opinion leaders in the clinical and scientific communities. ABV's network of these opinion leaders provides continuous critical insight and guidance to each portfolio company; and

(iii) Active involvement in portfolio companies.
ABV's principals bring extensive operating experience in achieving value-creating milestones in early-stage healthcare companies. ABV's active participation early in a portfolio company's life-cycle maximizes management's ability to navigate the changing technology landscape.